Podcasts about life sciences

At 25, Jace Yawnick was building a career in health and wellness sales, chasing growth, status, and the usual young adult fantasy of getting somewhere fast. Then his body stopped cooperating. Fatigue turned into chemotherapy. The diagnosis was primary mediastinal B cell non Hodgkin lymphoma, and the rest of his life split into before and after. Now in remission, he talks about cancer the way people actually live it, not the way nonprofits package it. He gets into survivorship, mental health, young adult isolation, and the deadening absurdity of prior authorization. One of the sharpest parts of the conversation lands on a simple American insult disguised as policy: treatment innovation means very little when insurance can still deny the scan, the drug, or the next step. Jace has seen that firsthand, including during routine monitoring after active treatment. This episode tracks what happens when a young cancer patient becomes a public voice and refuses to play mascot. It covers oncology, insurance, remission, advocacy, and the long mental hangover that follows survival. It also names the part too many institutions dodge: the system works great right up until it doesn't, and when it fails, patients get handed the bill, the panic, and a camera if they want anyone to care. RELATED LINKSJace Beats CancerJace Yawnick on LinkedImConquer Cancer ArticleCURE Today ArticlePyure BrandsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Microplastics are everywhere – in our water, in our food, and in our bodies. And while they are often the subject of headlines and new stories, researchers say there's still a lot to learn about how they may harm us. According to local experts, Rochester is a hot spot for the study of microplastics and health. This week, experts from across the country will be in town for a symposium exploring the latest research, challenges, and next steps for understanding how microplastics get into our environment and our bodies. Our guests preview that event and explain what we need to know about microplastics and protecting our health. In studio: Katrina Korfmacher, Ph.D., professor of environmental medicine and public health sciences at the University of Rochester and co-director of the Lake Ontario MicroPlastics Center Assemblymember Jen Lunsford, District 135 James Roussie, Ph.D., chief scientific officer and co-founder of SiMPore Christy Tyler, Ph.D., professor of environmental science in the Thomas H. Gosnell School of Life Sciences at the Rochester Institute of Technology and co-director of the Lake Ontario MicroPlastics Center ---Connections is supported by listeners like you. Head to our donation page to become a WXXI member today, support the show, and help us close the gap created by the rescission of federal funding.---Connections airs every weekday from noon-2 p.m. Join the conversation with questions or comments by phone at 1-844-295-TALK (8255) or 585-263-9994, email, Facebook or Twitter. Connections is also livestreamed on the WXXI News YouTube channel each day. You can watch live or access previous episodes here.---Do you have a story that needs to be shared? Pitch your story to Connections.

On this episode, host Justin Barnes shares a conversation with Tony Nunes, Sr. Manager, Healthcare & Life Sciences, AMD from a recent AI in Action virtual summit. Their discussion focused on, From Data to Decisions: Making AI Analytics Actually Actionable. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

At 20 years old, newly arrived from Puerto Rico and trying to build a future in science, Benjamin Suarez Jimenez found himself sitting in front of two senior faculty members accused of plagiarism. He knew the material. He had done the work. His mistake came from failing to cite class notes during an exam because nobody had told him that was expected. In a matter of minutes, he watched what felt like his entire career flash before him.On this episode of Standard Deviation, host Oliver Bogler examines the hidden architecture of academic science through the experiences of Dr. Benjamin Suarez Jimenez, Assistant Professor at the University of Rochester and a neuroscientist studying PTSD, anxiety, trauma, and spatial cognition through virtual reality and video game environments.Benjamin traces his path from Puerto Rico to the mainland United States, through the NIH, Columbia University, and eventually to leading his own laboratory. Along the way, he encountered a series of barriers that had little to do with scientific ability and everything to do with access to unwritten rules. From academic gatekeeping to grant writing expectations, he learned that success in biomedical research often depends on knowledge that never appears in a textbook.Oliver explores how those invisible obstacles shape careers, influence research funding, and determine who gains access to opportunity. The conversation also examines the Justice, Equity, Diversity, and Inclusion Program at the Life Science Editors Foundation, which pairs scientists from underrepresented backgrounds with experienced scientific editors. Through that mentorship, Benjamin transformed a critical grant proposal into a successful pilot award that helped launch an NIH R01 application.The discussion extends beyond one scientist's experience. Benjamin describes helping a former mentee navigate dissertation roadblocks that threatened her graduation, illustrating how institutional bureaucracy can delay careers and discourage talented researchers. Together, they explore the hidden administrative burden, cultural barriers, and bias that many scientists carry alongside their research, and what happens when someone who receives support turns around and opens the door for others.RELATED LINKSLife Science Editors FoundationBenjamin Suarez Jimenez LabDr. Benjamin Suarez JimenezBenjamin Suarez JimenezFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Austin's counterculture is still the ethos. The next chapter is what gets built on top of it. Karen Blashek, the editor-in-chief of Austin Home Magazine, took over a 21-year-old design publication with no editorial background and turned it into one of the city's most consequential platforms for naming what's already happening. We ask why Austin's design talent operates one neighborhood away from its tech talent and neither knows the other exists. What the city is telling people and the cultural infrastructure need to make it all compound: storytellers, convening spaces, named districts, and a  patronage layer.Agenda0:00 Austin Home as civic editing4:22 Why Austin lives outside15:04 Block parties and Old Sixth21:02 Personality vs. values27:07 Ground floors as infrastructure32:10 The public space czar idea37:01 Why Austin is a design capital41:01 Naming districts that exist45:07 Three roles every ecosystem needs53:37 If you don't tell the story, someone else will58:08 The patronage gap1:03:37 Rising stars, the talent leak1:09:50 Tech and culture flywheel1:15:40 Naming what's already hereGuest Bio and LinksKaren BlashekAustin Home MagazineGroundup IdeasCities and Ambition by Paul GrahamThe City That Lingers by Ryan PuzyckiTokyo is Reinventing the Downtown by Making More Than One by Richard FloridaKaren Zabarsky Blashek is Editor-in-Chief of Austin Home Magazine, a Hearst publication covering the intersection of architecture, interiors, development, and culture in one of America's fastest-evolving cities. She is also the founder of Ground Up, a creative studio for the built environment. Before returning to her native Texas, Blashek spent 13 years in New York where she led design for Kushner, one of the country's largest real estate developers with projects nationwide. -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

Bryon Hayes is a Life Sciences Consultant at Grantek. Bryon is passionate about technology and strives to use it for the benefit of others, which is why he focuses his energy on the life sciences industry. He takes pride in the fact that the technical solutions Grantek implements are helping those companies that manufacture life saving and beneficial medicines and therapeutic products. The Industry 4.0 Podcast with Grantek delivers a look into the world of manufacturing, with a focus on stories and trends that lead to better solutions.   Our guests will share tips and outcomes that will help improve your productivity. You will hear from leading providers of Industrial Control System hardware and software, Grantek experts and leaders at best-in-class industry associations that serve the Data Centers, Life Sciences, CPG and Food & Beverage industries.

Welcome to Health-e Law, Sheppard's podcast exploring the fascinating health tech topics and trends of the day. In the second part of this two-part episode, Cora Han, Chief Health Data Officer for University of California Health, joins partner and host Michael Orlando to discuss the current state of AI adoption across healthcare systems, including deployment, governance challenges, regulatory developments and the future of AI-enabled care delivery. What we discuss in this episode: The growing role and current state of AI adoption across healthcare delivery systems Ambient scribes, inbox management, coding assistance and other practical AI use cases Using AI to improve quality reporting and operational efficiency Opportunities for AI to address clinician shortages, burnout and healthcare access issues Expanding access to specialized care through AI-enabled care models The challenges of evaluating and governing a rapidly growing AI vendor ecosystem Adapting governance frameworks to keep pace with AI innovation Federal and state regulatory developments impacting healthcare AI adoption The importance of transparency in AI tools, including model development, performance and use Why implementation and workflow integration remain critical barriers to successful AI adoption Measuring ROI and real-world impact of AI tools in healthcare settings About Cora Han Cora Han is Chief Health Data Officer for University of California Health and Executive Director of the Center for Data-driven Insights and Innovation. She also serves as Co-Chair of the Health System and Provider Advisory Board for the Coalition for Health AI (CHAI).  Drawing on her extensive experience in AI strategy, regulatory advocacy, and data privacy, Cora leads efforts to establish consistent guardrails for the use of health data with AI vendors and third-party collaborators. Her work spans the full spectrum of health data challenges, from de-identification of clinical data to navigating HIPAA compliance and AI vendor relationships, making her a leading voice on responsible AI adoption in academic health systems. Before joining UC Health, Cora spent over ten years at the Federal Trade Commission, most recently as Senior Attorney in the Division of Privacy and Identity Protection, where she focused on data privacy and consumer protection, including a term as Counsel to the Director of the Bureau of Consumer Protection. Prior to her tenure at the FTC, she practiced at a leading international law firm, where she counseled clients on copyright and trademark matters. Cora also served as an Adjunct Professor of Consumer Protection Law at George Mason University School of Law for five years. Cora holds a BA in Government from Harvard University and a JD from the University of Chicago Law School. About Michael Orlando Michael Orlando is a partner in Sheppard's San Diego (Del Mar) office. He is team leader of the firm's Technology Transactions team, a member of the Life Sciences, Healthcare and Artificial Intelligence teams, and co-leader of the firm's Digital Health & Innovation team. Michael has more than 20 years of experience advising health technology companies, insurers, healthcare systems and providers, academic medical centers and research institutions, medical device manufacturers, pharmaceutical and wellness companies on intellectual property and business transactions in key strategic areas, including EHR systems procurement and integration, telehealth, mobile health applications, clinical decision support technologies, artificial intelligence, data use, wearable devices, remote patient monitoring, medical devices and equipment, research and collaborations, patent licenses, software licenses, joint ventures, mergers and acquisitions, revenue cycle management, and other outsourcing transactions.  Michael founded a software-as-a-service company before entering private practice and completed an in-house secondment at a publicly traded biotechnology company, an experience that informs his practical and business-focused approach to client engagements. Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.

When Artemis II lifted off this past April, marking humanity's return to the Moon, people across the world were captivated. It was a triumph decades in the making, but also shaped by painful loss. In this episode of Tiny Matters, we trace the legacy of the Space Shuttle Challenger disaster on its 40th anniversary, unpacking what went wrong both scientifically and organizationally, and how the event necessarily helped reshape NASA's safety culture. We hear firsthand from astronaut Terry Hart, who flew on Challenger less than two years before the accident, and from NASA's acting Chief of Safety and Mission Assurance, Nathan Vassberg, about how Challenger — and later, Columbia — reshaped the way NASA thinks about risk, and how those lessons were applied to Artemis II. We also hear from Vanessa Bentley, professor of applied ethics who teaches a course dissecting the conflict between managers and engineers that led to the tragedy.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Sarah Matt trained as a burn surgeon, working in a field where patients arrive with catastrophic injuries and survival depends on speed, skill, and resources. She left the bedside after confronting a limit that medicine does not like to admit. One physician can only see so many people in a day. The system surrounding those patients decides the rest. She moved into health technology, held leadership roles in startups, and built global infrastructure at Oracle to scale care across populations. Then she watched billions of dollars in digital health and AI initiatives stall out when they hit real clinical environments.This episode follows that pivot from surgeon to strategist and back into direct patient care in rural New York, where she now treats uninsured patients, migrant workers, and communities pushed to the margins. The conversation centers on a persistent failure across healthcare systems. Products get built for regulators, executives, and investors instead of the people who use them. The result shows up in failed adoption, broken workflows, prior authorization delays, and rising physician burnout.The discussion cuts through health policy language and lands on lived consequence. The system rewards speed over usability, scale over trust, and compliance over care. Patients absorb the fallout. Physicians carry the liability. The incentives remain intact.RELATED LINKSDr. Sarah MattThe Borderless Healthcare RevolutionThe Clinical RealistJessica FedererSovatoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Developing a cancer drug is one of the most expensive, slow, and failure-prone processes in modern science. PharosAI is trying to change that – by building multimodal, AI-ready datasets from donated cancer tissue samples and making them available to researchers, biotech companies, and clinicians.In this episode, Technical Director Adrian La Porta speaks with PharosAI's Dr Lucie Burgess (COO) and Dr Emma Colliver (Research Fellow) about what it takes to curate cancer data at scale, why federated learning matters for patient privacy, where AI is already transforming diagnostics, and what synthetic patients could mean for clinical trials.Whether you work in life sciences, pharma manufacturing, digital health, or clinical data governance, understanding how AI is reshaping the drug discovery pipeline has direct implications for how and when new facilities will need to be built. This one is worth your time.Topics covered:00:00 Introduction00:01 What is PharosAI?00:06 Why AI can fundamentally change cancer care00:08 The venture behind the mission00:12 Lowering the barrier for UK biotech00:16 Are we at an inflection point?00:20 AI in diagnostics – what's already working00:24 Misconceptions about AI in biotech00:30 Data – acquiring, cleaning, and structuring00:34 Patient privacy, consent, and NHS data00:37 What cancer care could look like in 10 years00:40 Why this work matters personallySend us Fan MailTo learn more about Bryden Wood's Design to Value philosophy, visit www.brydenwood.com. You can also follow Bryden Wood on LinkedIn.

Martine van Vugt is Executive VP en Chief Strategy Officer van Genmab.***Volg Leaders in Life Sciences via de website.Volg Leaders in Life Sciences via LinkedIn.Bezoek www.henkjanout.nl voor meer informatie over de host.***Vragen, suggesties of feedback? Graag! Stuur een email naar: henkjan.out@me.com***Vind jij de Leaders in Life Sciences podcast leuk? Dan zouden we het enorm waarderen als je een recensie zou willen achterlaten op Apple Podcasts of een vijf sterren beoordeling zou willen geven op Spotify.Jouw steun betekent veel voor ons, omdat het anderen kan aanmoedigen om de podcast ook te gaan beluisteren. Heel erg bedankt!***Leaders in Life Sciences wordt mede mogelijk gemaakt door Pivot Park, Pedersen & Partners en Johnson & Johnson Innovative Medicine.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Tyler Menichiello, chief editor at Bioprocess Online, host of the Better Biopharma podcast, and my Life Science Connect (LSC) colleague, convenes the broader LSC editorial team once again for a midyear discussion on what's happening now in the life sciences industry, and what's to come in the second half of the year. Topics include AI manufacturing regulations and navigating supply chain pressures, outsourcing trends and onshoring, biotech market signals and IPOs, clinical development's slow shift to digitization, the move toward organoids and non-animal models (NAMs) in discovery, RNA modality growing pains, and more.   Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Regulatory volatility, scientific‑grade context requirements, and entrenched legacy processes are creating a level of operational complexity in pharma that makes even high‑value AI initiatives difficult to move from concept to production. In this episode, Art Shectman, CEO at Elephant Ventures, examines with host Marilie Fouché how leaders can cut through that complexity by isolating a single, clearly defined workflow slice and rebuilding it for near‑term, dependable deployment rather than long‑range architectural perfection. The discussion highlights how removing outdated process assumptions, selecting an atomic workflow with organizational alignment, and aiming for a contained operational win enable pharma teams to build momentum and scale AI responsibly in highly regulated environments. Learn how consultants are winning business with evidence-based AI ROI and building long-term capabilities instead of chasing short-term gains. Download our free PDF report, "3 Keys to Thriving in the Coming Era of Automation," at emerj.com/cok1

What does it take to run successful clinical trials across borders? Tune in as Chris Boone (Group VP, Research, Health & Life Sciences at Oracle) and Alicia Baker McDowell (VP & Head of Global Regulatory Strategy at Fortrea) explore the shift from transactional outsourcing to truly co-created partnerships.They discuss how sponsors, CROs, and tech partners are redefining collaboration, tackling data fragmentation, and striking the right balance between global consistency and local execution to deliver more effective clinical trials worldwide.

In this episode, we analyze Indegene, a Life Sciences and Pharma-focused IT services company, and explore how AI is reshaping the IT industry. We discuss the right mental model for evaluating IT companies, the difference between horizontal and vertical IT businesses, outcome-based pricing, revenue per employee, business segments, growth drivers, financial performance, risks, and valuation. The episode also highlights why Indegene may benefit from AI through domain expertise, regulatory capabilities, and productivity gains.

How do you introduce AI into one of the world's most regulated industries? Dan Herron, Global VP of Digital Health at RWS, joins the Cultural Intelligence Podcast to discuss how life sciences teams can responsibly apply AI in clinical operations, COAs, and linguistic validation: * Why life sciences is uniquely complex for AI adoption, and why regulation, bias, and documentation matter so much * How AI can support faster workflows in low risk areas (green zones), while a human in the loop remains essential for patient facing and regulated content (red zones) * Why the future of linguistic validation is about responsible modernization, not automation for its own sake A conversation on AI with guardrails, the human in the loop imperative, and why the industry can't afford to wait for someone else to go first.

Realities Remixed, formerly known as Cloud Realities, launches a new season exploring the intersection of people, culture, industry and tech.Life sciences are at a turning point, where scientific innovation, regulatory pressure, and patient expectations collide with unprecedented advances in data, AI, and digital platforms. IT is no longer a supporting function but a critical driver of how therapies are discovered, developed, scaled, and delivered safely and at speed.This week, Dave and Rob kick off the Life Sciences mini‑series with Thorsten Rall, Global Industry Lead for Life Sciences at Capgemini, to exploring the current state of the sector, the key themes shaping the episodes ahead, and what it takes to drive better patient outcomes. TLDR00:30 – Introduction to Life Sciences and co‑host Thorsten Rall04:37 – Hang‑out: Navigating Waterloo Station07:50 – Deep dive with Thorsten Rall into the Life Sciences landscape28:03 - What are the main challenges in the sector and main themes45:31 – BBQ season is starting HostsDave Chapman:  https://www.linkedin.com/in/chapmandr/Esmee van de Giessen:  https://www.linkedin.com/in/esmeevandegiessen/Rob Kernahan:  https://www.linkedin.com/in/rob-kernahan/with co-host Thorsten Rall: https://www.linkedin.com/in/thorsten-alexander-rall-b232185/ ProductionMarcel van der Burg:  https://www.linkedin.com/in/marcel-vd-burg/Dave Chapman:  https://www.linkedin.com/in/chapmandr/ SoundBen Corbett:  https://www.linkedin.com/in/ben-corbett-3b6a11135/Louis Corbett:   https://www.linkedin.com/in/louis-corbett-087250264/ 'Realities Remixed' is an original podcast from Capgemini

Wockhardt's FDA approval of Zaynich marks a historic first, the only drug entirely discovered and developed by an Indian company to clear US-FDA scrutiny. ET’s pharma editor Vikas Dandekar and Rica Bhattacharyya talk to Habil Khorakiwala, Chairperson of Wockhardt who unpacks the 25-year innovation journey behind this milestone. From a deliberate pivot to antibiotics when big pharma was exiting the space, to navigating financial turbulence, asset sales, and regulatory hurdles, Khorakiwala reflects on strategic patience and scientific conviction. He also outlines peak sales projections of $1.5–2 billion, the US commercial roadmap led by daughter Zahabiya, and a robust pipeline of blockbusters ahead.You can follow Vikas Dandekar on his social media: X or Linkedin and Rica Bhattacharyya on her X and Linkedin Check out other interesting episodes like:ET Deep Dive: Swipe Left on Reality,India wants manufacturing at 25% of GDP — will AI in factories help?, Tanay Kothari Wants To Kill The Keyboard, From Doer to Director: The LinkedIn Playbook for the AI Agea, Semaglutide Goes Generic: Big Pharma’s Moat Breaks and much more. Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.See omnystudio.com/listener for privacy information.

In this episode of Tiny Show and Tell Us, we dive into the Plankton Manifesto and why these drifting, diverse organisms are so essential to life on Earth. Then we trace the nuclear magnetic resonance (NMR) roots of MRI, through a listener's personal experience as a patient and chemist.Check out This Guy Sucked here or wherever you get podcasts!We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

CEO of Bloom Burton's Brian Bloom discusses the themes of the 2025 Bloom Burton conference, return entrepreneurs in the Canadian Life Sciences landscape, and accelerating drug discovery with AI. Get full access to NPC Healthbiz Weekly at healthbiz.substack.com/subscribe

Tune in to Robert T. Howard, Esq., Co-chair of the Health Law Community Steering Committee, as he moderates a dynamic conversation with panelists Remi Mehner, Esq. and Amaru Sanchez, Esq., counsels in Akin's Health Care and Life Sciences practice, as they discuss the topic Food is Health/Medicine: Why Health Lawyers Should Start Paying Attention to Food Policy. This conversation introduces the concept of how nutritional interventions are being used to prevent and treat diet-related chronic diseases, and why this is relevant to those working in the health law and health policy space. The discussion opens with an overview of the concept of food is medicine, including key terms. Next the panelists inform the listeners about why health lawyers should start paying attention to food policy. The panel discusses actions and signals in the governmental landscape that indicate the importance and timeliness of this discussion. The panelists then discuss funding models, including federal, state, and private sector funding. Lastly, the panelists discuss food law and food policy developments that health lawyers should have on their radar.Please note, the positions and opinions expressed by the speakers are strictly their own, and do not necessarily represent the views of their employers, nor those of the D.C. Bar, its Board of Governors or co-sponsoring Communities and organizations.Thank You to our Sponsor!Posh is the 24/7 call answering service designed for legal professionals of all kinds. Save time and win business with an AI receptionist and team of live agents always at the ready. Capabilities include customized client intake, appointment scheduling, call screening and transferring, English- and Spanish-fluent receptionists, legal integrations, and much more. Simply set your availability and instructions, and Posh handles the rest. Get a free trial at posh.com/law or call 833-GET-POSH.

In the late 1980s, a child exposed to fallout from the Chernobyl disaster lay in a hospital bed while doctors told his family there were no clear answers and no reliable path forward. Decades later, that same child, Yan Leyfman, walks into exam rooms as a hematology oncology fellow, expected to deliver clarity inside a system that still runs on delay, uncertainty, and institutional self preservation.This episode traces the throughline from early life shaped by radiation exposure and hospice level uncertainty to a career inside academic medicine, translational research, and oncology media. Yan built his identity around survival and usefulness, moving from patient to physician while carrying the memory of what it feels like to sit on the other side of the table. He helped launch MedNews Week during the COVID crisis to push back on misinformation and expand access to medical knowledge, stepping into a public role while still in training.The conversation stays grounded in the friction between personal narrative and system reality. Clinical training demands efficiency, hierarchy, and emotional distance. Cancer care demands time, clarity, and human connection. Those forces collide in real patient encounters where prior authorization delays, insurance barriers, and fragmented care pathways shape outcomes as much as any treatment protocol.Yan speaks openly about mentorship, belonging, and the drive to make meaning out of survival. The discussion pushes further into what the healthcare system actually rewards, what it quietly strips away, and how quickly empathy can erode under institutional pressure. The episode also examines the role of medical media, where education, industry influence, and narrative control often blur together.This is a conversation about identity under construction, about what happens when someone who remembers powerlessness steps into a role that carries authority, and about whether that memory can survive long enough to change anything.RELATED LINKSYan Leyfman on LinkedInYan Leyfman on InstagramSurviving ChernobylFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Matthew Zachary is a brain cancer survivor, healthcare advocate, founder of Stupid Cancer and We the Patients, and host of Out of Patients. In April 2026, he returned to the stage at Merkin Hall near Lincoln Center for his first solo public piano concert in almost 22 years while launching his debut book, We the Patients: Understanding, Navigating, and Surviving America's Healthcare Nightmare.What unfolded became far larger than a concert.Over 2 hours, survivors, clinicians, advocates, nonprofit founders, journalists, pharmaceutical sponsors, and healthcare insiders gathered in one room to reflect on 30 years of survivorship, institutional failure, accidental advocacy, and the emotional afterlife of cancer. The evening moved through original piano performances, live chapter readings, and deeply personal conversations about infertility, disability, financial toxicity, insurance denials, grief, burnout, and what happens when patients spend decades navigating systems designed around transactions instead of continuity.Guests including Wendell Potter, Maimah Karmo, Craig Lustig, Shelly Fuld Nasso, Tamika Felder, and others reflected on how the modern cancer advocacy movement emerged largely because patients built parallel systems where healthcare infrastructure failed to meet human needs. The conversation explored how prior authorization, reimbursement incentives, administrative fragmentation, and institutional distrust continue shaping the patient experience across oncology and survivorship.The performance also marked a deeply personal milestone. After brain cancer compromised his left hand at age 21, Zachary spent 6 months rehabilitating both hands to return to public performance for the first time in over 2 decades. The result became part concert, part civic gathering, and part historical record of a generation of survivors who refused to disappear quietly.RELATED LINKSMZLIVE Official WebsiteMZLIVE YouTube VideoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Ian Tooke is the VP of Digital Transformation & AI at Grantek. Ian has a dual mandate at Grantek; overseeing Consulting & Digital Solutions while directing enterprise IT, AI strategy, and Marketing for a 230-person systems integrator serving regulated manufacturers.   With 30 years in manufacturing technology, Ian holds multiple patents and serves as a MESA International board member. His background spans strategy, marketing, partner management, and business development.. The Industry 4.0 Podcast with Grantek delivers a look into the world of manufacturing, with a focus on stories and trends that lead to better solutions.   Our guests will share tips and outcomes that will help improve your productivity. You will hear from leading providers of Industrial Control System hardware and software, Grantek experts and leaders at best-in-class industry associations that serve the Data Centers, Life Sciences, CPG and Food & Beverage industries.

What if a single unplugged power cord nearly derailed a top biotech leader's story—and ended up launching an episode packed with innovation, real connection, and a peek inside Philadelphia's hidden biotech gems? In this lively, uplifting conversation, Lou Diamond welcomes Robert Christmas, the connector behind the Pennsylvania Biotechnology Center and the Union League's Life Science Affinity Club. They dive into the unexpected journeys that lead scientists to solve some of humanity's biggest problems, the secrets behind Philly's “pharma belt,” and the power of community-driven innovation. Along the way, you'll find out why some of the most world-changing discoveries come from people with no personal stake—and how AI, chocolate, and mountain biking fit into the life of a master connector.Get the inside edge on biotech breakthroughs, community building, and some great behind-the-scenes laughs in this episode of Thrive Loud!00:02 - Show introduction and welcome00:25 - Hilarious technical misadventure: the unplugged cord 02:09 - Robert Christmas's entry into life sciences 03:33 - Overview of the Philadelphia region's biotech significance 04:19 - How the Pennsylvania Biotechnology Center started and grew 05:51 - Types of medical breakthroughs at the center 07:59 - Spotlight: scientists who brought drugs to market 08:34 - Robert Christmas on the Union League, Philly's historic Life Science Affinity Club 10:00 - Launching a new Life Science podcast 11:28 - The power and reach of Philly's innovation ecosystem 12:37 - How the work personally impacts Robert Christmas 14:32 - Where to find, support, and connect with these organizations 17:02 - Fun speed round: movies, food, activities, and more 19:52 - AI, workflow automation, and the next generation of collaboration 22:15 - Collaborating with Jeff Gibbert and future innovation 22:51 - Closing thoughts and gratitude from Lou Diamond

Did you know that over 75% of silent films have disappeared? The culprit: highly flammable film! We open this episode of Tiny Matters with a poker bet, a decades long grudge, and a garage full of film before we hop into the rise of nitrate (nitrocellulose) film and how it shaped film history. We chat with Robert Shanebrook, who literally wrote the book on Kodak film, and with collection manager Deborah Stoiber at the George Eastman Museum, the world's oldest photography museum and one of the oldest film archives. We talk about the science of preserving and conserving the nitrate films that have survived, and why it's so important for keeping cultural memories alive. Did you know that ‘George Eastman, Kodak, and the Birth of Consumer Photography' is a National Historic Chemical Landmark? Read more about it here. Check out Wow if True here or wherever you listen to podcasts!We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to Health-e Law, Sheppard's podcast exploring the fascinating health tech topics and trends of the day. In part one of this two-part episode, Cora Han, Chief Health Data Officer for University of California Health, joins partner and host Michael Orlando to discuss the adoption of Artificial Intelligence in healthcare, including the management of data privacy, vendor relationships and AI governance. What we discuss in this episode: De-identification of protected health information in practice The HIPAA standards for de-identification and when to apply them The unique challenges unstructured clinical notes present for re-identification risk A layered approach to de-identification, including automated tools and human review Third-party certification of de-identification processes Key contract provisions for protecting PHI when working with AI vendors Hidden data training clauses in vendor agreements The evolving AI vendor marketplace and contract strategy UC Health's federated governance model for AI and data governance Shadow AI use and the importance of safe experimentation The importance of legal and compliance teams engaging early in the AI adoption process About Cora Han Cora Han is Chief Health Data Officer for University of California Health and Executive Director of the Center for Data-driven Insights and Innovation. She also serves as Co-Chair of the Health System and Provider Advisory Board for the Coalition for Health AI (CHAI).  Drawing on her extensive experience in AI strategy, regulatory advocacy, and data privacy, Cora leads efforts to establish consistent guardrails for the use of health data with AI vendors and third-party collaborators. Her work spans the full spectrum of health data challenges, from de-identification of clinical data to navigating HIPAA compliance and AI vendor relationships, making her a leading voice on responsible AI adoption in academic health systems. Before joining UC Health, Cora spent over ten years at the Federal Trade Commission, most recently as Senior Attorney in the Division of Privacy and Identity Protection, where she focused on data privacy and consumer protection, including a term as Counsel to the Director of the Bureau of Consumer Protection. Prior to her tenure at the FTC, she practiced at a leading international law firm, where she counseled clients on copyright and trademark matters. Cora also served as an Adjunct Professor of Consumer Protection Law at George Mason University School of Law for five years. Cora holds a BA in Government from Harvard University and a JD from the University of Chicago Law School. About Michael Orlando Michael Orlando is a partner in Sheppard's San Diego (Del Mar) office. He is team leader of the firm's Technology Transactions team, a member of the Life Sciences, Healthcare and Artificial Intelligence teams, and co-leader of the firm's Digital Health & Innovation team. Michael has more than 20 years of experience advising health technology companies, insurers, healthcare systems and providers, academic medical centers and research institutions, medical device manufacturers, pharmaceutical and wellness companies on intellectual property and business transactions in key strategic areas, including EHR systems procurement and integration, telehealth, mobile health applications, clinical decision support technologies, artificial intelligence, data use, wearable devices, remote patient monitoring, medical devices and equipment, research and collaborations, patent licenses, software licenses, joint ventures, mergers and acquisitions, revenue cycle management, and other outsourcing transactions.  Michael founded a software-as-a-service company before entering private practice and completed an in-house secondment at a publicly traded biotechnology company, an experience that informs his practical and business-focused approach to client engagements.   Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.

In December 1996, a 37 year old pharmaceutical executive sat in a Borders bookstore reading medical textbooks on the floor, trying to understand a disease she had never heard of. Multiple myeloma carried a three year prognosis. Her daughter was 18 months old. Her father had just died of cancer. Within weeks, she pushed her doctors to say the quiet part clearly. This would likely end her life before her child entered kindergarten.Kathy Giusti refused to accept passive survival. She built a plan while the system offered fragments. She interviewed oncologists and fertility specialists at the same time. She pursued IVF to have a second child while preparing for treatment. She stayed employed to keep insurance coverage. Every decision carried financial, medical, and emotional risk.That same urgency exposed a deeper failure. Cancer research moved slowly. Academic centers guarded data. Clinical trials lacked coordination. Patients entered a system that demanded compliance without providing clarity. Giusti responded by building the Multiple Myeloma Research Foundation, not as a support group, but as an operating engine to accelerate drug development, fund research, and force collaboration across institutions.This episode tracks the tension between individual agency and systemic failure. Giusti describes how patients navigate diagnosis, insurance barriers, and fragmented care in real time. She explains how data, genomics, and clinical trials reshape cancer treatment while still leaving patients responsible for decisions they are not trained to make. She addresses disparities in access, the limits of early detection, and the reality that progress in oncology often depends on speed, funding, and alignment of incentives.The conversation moves between lived experience and structural critique. It names the cost of delay, the burden placed on patients to act as their own advocate, and the tradeoffs required to push a system forward that still protects itself first.⸻RELATED LINKSKathy GiustiMultiple Myeloma Research FoundationFatal to FearlessAmerican Society of Hematology⸻FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mary Varghese Presti didn't plan to end up running healthcare AI for one of the most powerful technology companies on earth. She came to the United States at four years old, the daughter of an Indian nurse recruited by Penn Medicine during India's brain drain era. Growing up in Philadelphia in the shadow of one of the world's top nursing schools, she watched her mother and many of the women in her Indian community use the nursing profession as a vehicle for immigration, education, and female empowerment in a generation where very few professional doors were open to them. She began her career as a pediatric nurse at Johns Hopkins. On the floors, she saw everything in a single shift: early cases of congenital HIV, double lung transplants in young children, East Baltimore asthmatic exacerbations. And she kept asking the same question over and over again: why is healthcare organized this way? That single question became a career. From bedside nursing she moved into consulting, working on harmonizing clinical quality measures across NCQA, NQF, AMA and CMS, foundational work that paved the way for value-based care. She helped shape the policy framework that led to meaningful use and the electronic health record adoption wave. She joined Pfizer at the exact moment Lipitor was losing patent protection, watching 10 billion dollars in revenue evaporate in a single year while the entire pharma commercial model was rewritten around her. Today she is the Corporate Vice President and Chief Operating Officer of Microsoft's Health & Life Sciences organization, leading at what she calls one of the few generational shifts in technology in her lifetime. In this episode of Inspiring Women, host Laurie McGraw sits down with Mary to talk about the arc from bedside nursing to Microsoft, from the Manila folder era of medicine to a Stanford pilot where AI agents now compress cancer treatment decisions from weeks and months down to days. They go deep on the AI that hundreds of thousands of physicians are already using today, why nurses describing themselves as "data entry analysts" broke something in her, and what it actually means to build technology that fades into the background instead of getting between a patient and the person caring for them. They discuss: - Growing up as the daughter of an immigrant nurse, and what nursing did for female empowerment in her mother's generation in India - Why she began her career at Johns Hopkins and the moment as a 24-year-old floor nurse that turned her into a systems thinker - The four-act arc of her career across nursing, policy, pharma and technology, and why every zig and zag felt rational at the time - Inside Pfizer during the Lipitor patent cliff, when one drug lost 10 billion dollars in revenue in a single year - Why healthcare still tolerates a digital experience nobody would accept from Uber, Venmo, or online banking - Dragon Copilot for physicians, and how it removes the keyboard from between doctor and patient - Dragon Copilot for nurses, and why nursing workflows demand a fundamentally different technology design - The physical, emotional and cognitive burden that AI is finally lifting off frontline clinicians - The Stanford multi-agent tumor board experiment compressing cancer treatment decisions from weeks to days - Why she refuses to be put in a box as clinician, operator, strategist or policy person, and what a lattice career actually looks like - What she means when she says she expects to remain intrepid for the next five years If you care about the future of healthcare, the real impact of AI on frontline workers, or what a non-linear career built across nursing, policy, pharma and tech actually looks like, this one is for you.

The Big Unlock · Sally Ann Frank, Global Lead – Health & Life Sciences, Microsoft for Startups In this episode, Sally Ann Frank, Global Lead for Health and Life Sciences at Microsoft for Startups, discusses how AI is moving beyond experimentation toward measurable enterprise impact. She emphasizes that the most successful startups differentiate themselves not just through technology innovation, but through evolving business models, strong customer discovery practices, and a coachable mindset grounded in strategic mentorship. Sally explores the challenge of “pilot purgatory,” noting that founders must design for production from day one. Establishing clear ROI frameworks and demonstrating early value are essential to maintaining momentum and avoiding the law of diminishing interest often seen in stalled pilots. Looking toward 2026, Sally envisions a “show me the money” era centered on four bridges: expanding global access through virtual technology to democratize care, closing the investment gap in women's health beyond reproductive care, advancing AI-driven precision medicine through genetics for individualized treatment, and shifting healthcare from reactive treatment toward preventative longevity. Ultimately, the conversation highlights that lasting success in AI will belong to organizations that evolve into trusted advisors, consistently delivering value at every interaction. Take a listen. This guest appearance was facilitated through conversations initiated at HIMSS.

Suspected Ebola cases in eastern Congo have climbed past 900, with at least 119 deaths, as the World Health Organization warns that the outbreak poses a ‘very high’ risk in the country, though it sees a low risk of spreading globally. Arson attacks on Ebola treatment centers, anger over tightly controlled burials and mistrust of authorities are fueling community backlash, complicating efforts to fight a virus with no approved vaccine. KAN's Mark Weiss spoke with immunologist Prof Cyrille Cohen, the Dean of the Faculty of Life Sciences at Bar Ilan University. (Photo: Reuters)See omnystudio.com/listener for privacy information.

Bakery Showcase is Canada's biggest baking show. Hosted by the Baking Association of Canada [https://www.baking.ca] (BAC), this well-known event is the ideal spot to catch up on the latest trends and innovations in the Canadian baking industry. In this episode of BAKED in Science, host Mark Floerke is joined by several bakery professionals to discuss bakery equipment, ingredients, and innovation solutions. Keith Ellis is the Director of Sales for Eastern Canada at Harvest Corporation (https://www.harvestbakeryequipment.com). Since 1964, Harvest Corporation has been committed to providing the food industry in North America and beyond with top-quality bakery equipment and exceptional service. Ender Ceber is the Founder and CEO of Chef Ceber, Inc. Chef Ceber (https://chefceber.com) is a premier chocolate and desserts brand created to bring traditional craftsmanship together with modern gastronomy. Spiromatic (https://www.spiromatic.com/en/) is a global leader in automated ingredient handling systems, specializing in flour storage, pneumatic conveying, dosing solutions, and sourdough systems for industrial bakeries and food manufacturers. E.B. Russell is the Senior Sales Manager at Lesaffre North America. The Lesaffre Group (https://lesaffrebaking.com) is a key global player in baking, food taste and pleasure, healthcare, and industrial biotechnology. Their family history spans over 170 years and in over 50 countries, and lives each day through our more than 11,000 employees. Mathias Weigel is the Head of International Sales at IREKS. IREKS (https://www.ireks.com/en/) is an internationally operating family company with its headquarters in Kulmbach, Germany, and customers in 90 countries worldwide. Stephen Brand is a Machine Operator at Barry Callebaut. Barry Callebaut (https://www.barry-callebaut.com/) is the world's leading maker of high-quality chocolate and cocoa products. Tina Tourangeau is the Client Development Manager, and Kate Tomic is the Business Team Director at Caldic North America. Caldic (https://www.caldic.com/en-us) powers innovation coast to coast by delivering tailored solutions and market-ready ingredients to the Life Sciences, Personal Care, and Biopharma markets. Arla Pro (https://www.arlapro.com/en/) is the dedicated food service business of the global dairy co-operative Arla Foods. Arla (https://www.arla.com) is a cooperative of dairy farmers who produce milk and dairy products for consumers worldwide. Daniel Moir is the Senior National Account Executive at Ardent Mills. Ardent Mills (https://www.ardentmills.com) is North America's leading flour supplier, producing multi-use flours, whole grains, and supported by 40+ flour mills and bakery-mix facilities. From the Show Floor While at the showcase, some topics covered include: Affordable bakery equipment Protein solutions for desserts Ingredient handling technology Fermentation Shelf-life extension Sourdough Bread mixes Chocolate products Ingredient supply Cheese ingredients for baking Cocoa replacement solutions

In this episode of The Crossman Conversation, John Crossman speaks with Curtis Sprouse—life sciences entrepreneur, board advisor, and founder of EurekaConnect—about how behavioral analytics transform leadership effectiveness. Learn how CEOs identify blind spots, build resilient teams, and scale innovation from bench to bedside in the age of AI.

Recorded last week at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with Kristen Fortney, Ph.D., co-founder and CEO of BioAge Labs. In a conversation with Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, Fortney discusses the company’s decade-long effort to use human aging data to identify drug targets tied to longevity and age-related disease. She also breaks down BioAge’s oral NLRP3 inhibitor, BGE-102, which the company believes could have applications across cardiovascular, ocular and CNS diseases by targeting inflammation linked to aging biology. The conversation also explores why pharma companies are paying closer attention to aging and exercise biology, how GLP-1 drugs are reshaping conversations around prevention and what the future of aging-related medicine could look like. To learn more about the topics in this episode: BioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS Novartis, BioAge take on age-related diseases in $550M pact What can we learn from 2024’s biotech IPOs? See omnystudio.com/listener for privacy information.

Catherine is a Global Market Intelligence Manager in the Life Sciences industry. In this episode we talk about:  How to be the person job descriptions are written for.  Creating new opportunities within your organisation in a declining jobs market.  How to be CEO of your own mind and be free of old patterns of thinking.  Connect with Catherine  https://www.linkedin.com/in/catherine-mcdonnell-5a9ab722/  Kickstart your Intentional Careers Journey  Take the Career Accelerator Scorecard: https://scorecard.intentional-careers.com/strategy  Register for a free Intentional Careers workshop: https://intentional-careers.com/workshop/  Read The Book 'Intentional Careers for STEM Women': https://amzn.eu/d/bL9r8h0    Connect with Hannah  https://hannahnikeroberts.com/  www.linkedin.com/in/hannahrobertscoaching  www.facebook.com/drhannahroberts  X (Twitter) @HannahNikeR  Instagram @drhannahroberts  TikTok @drhannahroberts  YouTube @drhannahroberts 

Updated re-release. A year ago we left one question unresolved. Where do foundational AI models end and where do the applications begin? Nick Tippmann returns in a fresh epilogue.  A year on, the tension has only sharpened. Specificity is the differentiator when inches matter. Nick Tippmann, founding partner of TipTop VC, explains how vertical AI is rewriting the software industry by going deeper instead of wider. From the transition beyond SaaS to the gray zone between foundational models and high-stakes applications, we get into how vertical AI can transform laggard industries and why Austin might lead the race.The Agenda00:00 Defining vertical AI05:07 Where general AI fails09:36 Vertical AI software, not just chatbots16:44 Pricing logic after the seat model24:04 Underwriting at pre-seed and seed 27:20 Capital intensity and seed-strapping36:48 TAM analysis and the Frontiers Market example41:46 OpenAI's Instacart hire and the gray zone45:55 Austin as a vertical AI hub58:21 Epilogue: Where the models end and applications beginGuest Links and BiosNick Tippmann, TipTop VCNick Tippmann is the Founder and Managing Partner of TipTop Ventures, an early-stage venture fund focused on Vertical AI. Before becoming an investor, Nick spent nearly a decade as a founding team member and CMO at Greenlight Guru, where he helped scale the company from zero to category leader with more than 250 employees, tens of millions in ARR, and a nine-figure investment from JMI Equity.An operator turned investor, Nick now partners with founders building industry-specific AI and software businesses, bringing hands-on experience in go-to-market strategy, scaling, community building, fundraising, and company development. He has also been an active angel investor since 2021, with more than 100 startup investments. -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

Healthcare technology should quietly remove friction and reduce burden so clinicians can focus on what matters most: caring for patients in a more human way. In this episode, Lisa Gulker, Chief Nursing Officer at Oracle Health and Life Sciences, discusses how Oracle is rethinking healthcare technology by building AI directly into the foundation of its systems rather than layering it on as an afterthought. She explains how this approach can help clinicians spend less time in the chart, reduce workflow fragmentation, and make technology feel more seamless in the care experience. Lisa also shares how Oracle is applying these capabilities across providers, life sciences, and payers, creating opportunities to accelerate research, improve clinical trial matching, streamline prior authorization, and reduce administrative burden across the ecosystem. Throughout the conversation, she brings a nurse leader's perspective to a central question in healthcare innovation: how do we use technology to make care feel more human, not less? Tune in and learn how embedded AI could reshape the healthcare experience for clinicians, staff, researchers, payers, and patients alike! Resources: Connect with and follow Lisa Gulker on LinkedIn. Follow Oracle Health on LinkedIn and visit their website!

In this episode of Tiny Show and Tell Us, a listener asks: Could we still be carrying air from our very first breath? Deboki unpack's residual lung volume, gas exchange, and a forensic technique used to determine whether or not someone drowned. Then, the conversation turns to women's health and bleeding disorders after a listener shares their experience living with Von Willebrand disease — the most common bleeding disorder. Sam explores what the condition is, how it was discovered, why it disproportionately affects women, and how normalizing heavy, painful periods is not just frustrating but has serious medical consequences.Check out Pale Blue Pod here or wherever you get podcasts!We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In some of our previous episodes, we've explored the interesting paths that  Wolf Greenfield attorneys have taken as they eventually made their way to IP law. One thing that separates Wolf Greenfield from other firms is the depth of real-world experience many of its attorneys possess. In fact, over half of the professionals at Wolf Greenfield worked in science and technology industries prior to entering law.Kevin MacDonald, a Shareholder in Wolf Greenfield's Biotechnology practice, is an ideal example. After earning a degree in biology at Boston College, Kevin went to England to get his Master's in Molecular Biology and then back to North America for his PhD at McGill University's Institute of Parasitology in Montreal. Before his graduate studies and eventually going to law school, Kevin worked as a Life Science and Healthcare Industry Analyst at the British Consulate-General in Boston.In this episode of IP Talk with Wolf Greenfield,  Kevin discusses his path from the world of science to IP law and his current work assisting clients with IP strategy, portfolio management, and patent prosecution and counseling.Here are a few highlights from the conversation:01:18 - Kevin's background in biology02:33 - How Kevin became interested in parasitology03:10 - Serving as an analyst at the British Consulate-General04:21 - Making the switch to law05:38 - The challenges of transitioning from science to a legal career06:21 - Kevin's current practice at Wolf Greenfield07:20 - Some of the most exciting things happening in biopharma today08:18 - Kevin's efforts as a board member of the British American Business Council of New England###

This episode,  Heather and Matthew welcome attorney John Erwin, the newest addition to Maynard Nexsen's Health Care and Life Sciences team, to discuss the landscape of mergers and acquisitions in the life sciences industry. John shares insight from his decades of experience in complex healthcare and life sciences transactions, including how data considerations and emerging technologies are shaping deal activity. We also discuss regions like North Carolina's Research Triangle that continue to attract investment. Tune in for a look at how transactional strategy is adapting and what may lie ahead for life sciences over the next year!

At 19, Shlomit woke up unable to speak. The right side of her body went numb. An emergency room sent her home and called it stress. That moment did not end in a diagnosis that changed policy or triggered reform. It sent her into a decade long pursuit of understanding how the brain fails language and how the healthcare system fails patients who cannot advocate for themselves.Shlomit trained as a speech language pathologist and spent years inside acute care hospitals and ICUs, performing endoscopies and treating patients with brain injury, stroke, and dysphagia. She watched medical teams rotate in and out, deliver dense updates, and leave families nodding without comprehension. She stayed behind and translated. Every day, patients told her she was the only one who explained what was happening. That gap is not an accident. Hospital systems optimize for throughput, not understanding. Patients move through beds based on cost, not readiness. Discharge planning becomes a financial decision wrapped in clinical language. A stay under 48 hours can shift the insurance burden dramatically, leaving patients exposed to higher out of pocket costs. Shlomit left the system and built Patient Path NYC, a private patient advocacy service. She now spends 15 to 20 hours a week per client reading charts, coordinating care teams, and translating medical decisions into plain language. Her work sits in the uncomfortable space between healthcare policy and lived experience. Families pay out of pocket to understand their own care. Hospitals benefit from the clarity she provides while maintaining the same structural incentives that created the confusion.This conversation tracks the human cost of fragmented care, the economics behind discharge decisions, and the quiet reality that patients who cannot communicate clearly often lose control of their own outcomes.RELATED LINKSShlomit LibertyShlomit Liberty on LinkedInPatient Path NYCBoard Certified Patient AdvocateFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Your AI plan can't outrun your data. Adam Marko, life science field CTO at Hammerspace, joins the podcast to unpack the problem almost every biotech, pharma, and biomedical research group runs into: unstructured data that are siloed, fragmented, and scattered across storage systems, sites, and clouds. With host Jessica StLouis, they talk through what “data orchestration” means when building an AI-ready data foundation, infrastructure constraints and the tiered storage patterns that help teams keep AI and HPC workloads moving, and why life sciences are in a uniquely tough spot. Plus, Marko shares a preview of his presentation at Bio-IT World Conference & Expo in Boston.  If you care about faster discovery, smoother AI workflows, and fewer manual file moves, subscribe, share this with a colleague, and rate or review so more researchers can find the conversation. Links from this episode:  From Data Chaos to Discovery: Building the Data Foundation for AI-Ready Scientific Research Bio-IT World Conference & Expo Bio-IT World BioTeam Hammerspace Bio-IT World's Trends from the Trenches podcast delivers your insider's look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. 

Live from BPI West

In 2020, developmental biologist Dr. Crystal Rogers drove the country roads outside Davis, California crying between grant rejections, wondering whether she was about to lose her lab, her career, and the scientific future she had spent years building. She had already done what academia tells young scientists to do. She earned the credentials. She landed a faculty position at UC Davis. She built a lab. Then the real test began.On this episode of Standard Deviation, Dr. Oliver Bogler examines the unspoken rules that determine which scientists survive academic research and which quietly disappear from it. The conversation follows Crystal Rogers and cancer biologist Dr. Michelle Mendoza as they collide with the “Hidden Curriculum” of biomedical science: the unwritten rhetoric, institutional signaling, and grant writing strategies that often decide who receives funding, tenure, and long term stability.Michelle Mendoza entered a tenure track position at the Huntsman Cancer Institute while raising 3 children, navigating a divorce, and trying to secure major NIH funding during COVID. What looked like objective scientific review turned out to depend heavily on persuasion, presentation, and insider fluency. Established researchers could promise massive research agendas based on reputation alone. Junior investigators faced a completely different standard.Oliver traces how the Life Science Editors Foundation and its JEDI program intervened by pairing scientists with former editors from journals including Cell and Nature. The work had little to do with commas or grammar. Editors challenged logic, structure, and scientific framing before grant reviewers could destroy an application in public.Both researchers eventually secured career defining grants. One realized she would keep her job and not have to move her family. The other celebrated by ordering a personalized “DEV BIO” license plate and driving through Davis blasting nineties hip hop and Beyoncé.The episode exposes how biomedical research funding rewards institutional fluency as much as scientific talent, and how hidden systems inside academic medicine continue shaping who gets to stay in science long enough to make discoveries.RELATED LINKSDr. Crystal Rogers LinkedInDr. Crystal Rogers Faculty PageDr. Crystal Rogers LabDr. Michelle Mendoza LinkedInDr. Michelle Mendoza Faculty PageHuntsman Cancer Institute Mendoza LabLife Science Editors FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of The Global Marketing Show, international project leader Franziska Höhne shares a practical, real-world framework for managing global teams where precision, compliance, and cross-border alignment are non-negotiable. Drawing from nearly 20 years of experience leading complex international projects, Höhne makes one thing clear: you're not managing functions, you're aligning humans across cultures. In regulated environments, the ability to build trust across geographies becomes a core operational capability. She emphasizes the importance of humanizing virtual teams, ensuring that colleagues don't just interact as roles on a screen, but as real people with context, constraints, and different ways of working. A major theme in the conversation is how language creates hidden risk, even when everyone speaks English. Subtle phrases like “let's revisit the timeline” can signal urgency in one culture and optional follow-up in another. In high-stakes environments like clinical development, regulatory submissions, or global product rollouts, these small misunderstandings can have outsized consequences.  To navigate this complexity, she introduces a simple but powerful framework built on three pillars: Human connection: Build trust by seeing people, not just roles Language precision: Be intentional with wording, tone, and expectations Operational structure: Standardize how teams communicate, document, and respond across regions This framework becomes especially critical when managing teams across multiple time zones. Höhne shares a practical solution: rotate meeting times so no single region consistently absorbs the burden of off-hours collaboration. Combined with clearly defined communication protocols and documentation standards, this creates a more equitable and effective global operating model. The episode also reinforces a key insight for regulated industries: while English may be the working language internally, translation and localization remain essential for external-facing materials. Precision isn't optional when compliance and clarity are on the line. For leaders in Life Sciences, medical devices, manufacturing, CPG brands, and other regulated sectors, the takeaway is direct: global success depends on how well your teams communicate across borders, not just what they build.  Check out The Global Marketing Show Blog.

In the early 1930s, a “new and improved” eyelash dye called Lash Lure blinded more than a dozen women, ultimately forcing the FDA to pass new regulations on cosmetics. Nearly a century later, beauty remains far safer than it was in the past, but you could argue that beauty marketing has become far more insidious, with vague language and chemophobic claims to push consumers toward products. In this episode, we chat with cosmetic chemist and science communicator Michelle Wong to unpack the booming “clean beauty” industry, including a conversation about parabens and fragrances and how chemophobia (a fear of chemicals) early in life can become a gateway to broader anti-science thinking, including anti-vax. You can follow Michelle at @LabMuffinBeautyScience on Instagram, TikTok, and YouTube where she makes longer explainer videos. Check out Wow if True here or wherever you listen to podcasts!We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2008, Katy Talento walked away from Capitol Hill and into a Catholic convent. Within a year, she walked out. Within another decade, she sat inside the White House shaping health policy. Somewhere in between, she got labeled “infertile” after a single cycle of testing and spent years believing it.That label stuck. The pain that came before it never got investigated. Doctors offered birth control and moved on. No one asked why her body was struggling. No one followed the thread.Talento built her career inside the very systems she now critiques. She worked on federal health policy, global disease programs, and later advised the Trump administration on healthcare reform. She helped advance price transparency rules in a system where hospitals can still list 457 different prices for the same service.Then she left.Now she builds employer health plans that bypass insurers, PBMs, and traditional networks. Her approach replaces insurance contracts with direct payment, nurse navigators, and cost sharing models that promise simplicity but raise hard questions about risk and protection.This conversation sits in that tension.Talento describes a healthcare system shaped by layered incentives, where insurers, hospitals, and intermediaries profit from complexity. She argues that employers hold the leverage to disrupt it. The host pushes on what happens when patients fall outside those structures, when contracts disappear, and when community based models fail.The episode moves through infertility, misdiagnosis, insurance design, and the mechanics of employer sponsored care. It tracks how policy decisions made in Washington ripple into exam rooms, billing departments, and family lives.It also confronts a harder truth.Even insiders who understand the system can still get caught in it.RELATED LINKSAllBetter HealthKaty TalentoThem Before UsAn Arm and a LegRelentless Health ValueFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Hosts Heather and Lauren are joined by Leslie Isenhour, Dean of Biotechnologies and North Carolina BioNetwork Capstone Center at Wake Tech Community College. With the growing demand for life sciences talent in North Carolina, Dean Isenhour shares how Wake Take is preparing the community through customized training programs, apprenticeships, and early exposure at the high school level. We discuss what draws major companies to the region and how community colleges partner with industry to close skill gaps, as well as the role of workforce development in supporting continued growth in biopharmaceutical manufacturing. Tune in to hear how education, infrastructure, and community investment come together to build a strong and sustainable talent pipeline in North Carolina!

Have you checked out ACS' new podcast Chain Reaction? Today we're bringing Tiny Matters listeners one of our favorite episodes! Chemistry doesn't just shape conflict — conflict shapes chemistry. And at no time in history is that more apparent than during the two world wars. Historian Alison McManus recounts how the race to weaponize toxic gases like chlorine and mustard gas transformed chemists into key military players, spurred industrial growth, and ignited an international arms race during WWI. However, some battles of the world wars weren't waged against an opposing army, but against diseases that soldiers caught while in combat. Journalist Karen Masterson reveals how WWII triggered a massive scientific mobilization — a secret, high‑stakes search for synthetic quinine and antimalarial drugs that would ultimately help seed the modern pharmaceutical industry. Packed with espionage, innovation, and ethical dilemmas, this episode uncovers how war accelerated chemistry in ways that still shape science today.Available wherever you get podcasts! Transcripts and episode sources at acs.org/chainreactionSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In a wooded campground cabin in the early 2000s, 19 year old Ben Unger stood in the doorway and watched 20 naked men form a circle around a crying teenager. A counselor held up two tangerines and shouted, “These are your balls.” The exercise claimed to cure same sex attraction by forcing young men to “reclaim” their masculinity from overbearing mothers. Phones had been confiscated. Parents had paid thousands of dollars. Religion supplied the script. Pseudoscience supplied the props.Ben had grown up in an Orthodox Jewish community in Brooklyn and later studied in Israel to become a rabbi. When he admitted he felt attracted to men, rabbis told him to eat 7 figs a day, immerse in a ritual bath 5 times daily, or marry a woman and trust that “if there's friction, it works.” At 19, he entered conversion therapy through an organization called Jews Offering New Alternatives to Homosexuality, known as JONAH. He left with depression, religious trauma, and 6 months of silence toward the mother he had been taught to blame.Years later, represented by the Southern Poverty Law Center, Ben helped sue JONAH for consumer fraud in a landmark New Jersey case. The argument centered on evidence, not theology. Sexual orientation cannot be changed. The jury deliberated for 3 hours and ruled against the organization. The verdict helped reshape how states regulate conversion therapy and protect minors from psychological harm disguised as treatment.Today, Ben runs Buff Personal Training in New York City, a gym built on autonomy, mental health, and self respect. His story traces the arc from institutional control to self authorship. The conversation examines religion, LGBTQ rights, conversion therapy, consumer protection law, and the lasting cost of being told your identity is a disorder.RELATED LINKSBen Unger on LinkedInBen Unger on InstagramBUF Personal TrainingSouthern Poverty Law CenterJONAHFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.